Literature DB >> 17359486

Genetic and environmental determinants of the PON-1 phenotype.

M Roest1, T M van Himbergen, A B Barendrecht, P H M Peeters, Y T van der Schouw, H A M Voorbij.   

Abstract

BACKGROUND: Paraoxonase (PON-1) is a high-density lipoprotein (HDL)-associated enzyme that may protect against cardiovascular disease (CVD), because it hydrolyses oxidized phospholipids of low-density lipoprotein (LDL) and therefore prevents the detrimental effects on the arterial wall. The current report describes the determinants of PON-1 bioavailability and activity.
MATERIALS AND METHODS: This is the largest (n = 1527) cross-sectional evaluation performed on PON-1 genotypes (Q192R, T-107C and L55M) and environmental determinants to PON-1 catalytic activity and bioavailability in serum of postmenopausal women. PON-1 catalytic activity and PON-1 bioavailability were measured, in vitro, with a paraoxon hydrolysis assay and a phenylacetate hydrolysis assay, respectively.
RESULTS: The major determinant of paraoxon hydrolytic activity is the Q192R genotype, but there was also a relation with the C-107T and L55M genotype, HDL levels and alcohol consumption. Phenylacetate hydrolytic activity was most strongly affected by the C-107T genotype followed by the L55M genotype, HDL levels, alcohol consumption and smoking.
CONCLUSIONS: PON-1 Q192R, C-107T and L55M genotype, alcohol consumption, smoking and HDL levels are determinants of serum PON-1 phenotype. The contributions of the genetic markers to the PON-1 phenotype are stronger than the contributions of the lifestyle determinants.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17359486     DOI: 10.1111/j.1365-2362.2007.01769.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  14 in total

1.  Neuropsychological and psychiatric functioning in sheep farmers exposed to low levels of organophosphate pesticides.

Authors:  Sarah Jane Mackenzie Ross; Chris Ray Brewin; Helen Valerie Curran; Clement Eugene Furlong; Kelly Michelle Abraham-Smith; Virginia Harrison
Journal:  Neurotoxicol Teratol       Date:  2010-03-20       Impact factor: 3.763

2.  Paraoxonase 1 (PON1) status and substrate hydrolysis.

Authors:  Rebecca J Richter; Gail P Jarvik; Clement E Furlong
Journal:  Toxicol Appl Pharmacol       Date:  2008-11-13       Impact factor: 4.219

3.  Paraoxonase 1 polymorphisms and risk of myocardial infarction in women and men.

Authors:  Kenneth J Mukamal; Jennifer K Pai; Majken K Jensen; Eric B Rimm
Journal:  Circ J       Date:  2009-05-15       Impact factor: 2.993

4.  The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters.

Authors:  Hossein Z Mirdamadi; Ferenc Sztanek; Zoltan Derdak; Ildiko Seres; Mariann Harangi; György Paragh
Journal:  Br J Clin Pharmacol       Date:  2008-09       Impact factor: 4.335

5.  Determinants of variation in human serum paraoxonase activity.

Authors:  D L Rainwater; S Rutherford; T D Dyer; E D Rainwater; S A Cole; J L Vandeberg; L Almasy; J Blangero; J W Maccluer; M C Mahaney
Journal:  Heredity (Edinb)       Date:  2008-10-29       Impact factor: 3.821

6.  Determination of paraoxonase 1 status without the use of toxic organophosphate substrates.

Authors:  Rebecca J Richter; Gail P Jarvik; Clement E Furlong
Journal:  Circ Cardiovasc Genet       Date:  2008-12

7.  The influence of renal function on the association of rs854560 polymorphism of paraoxonase 1 gene with long-term prognosis in patients after myocardial infarction.

Authors:  Anna Szpakowicz; Witold Pepinski; Ewa Waszkiewicz; Dominika Maciorkowska; Małgorzata Skawronska; Anna Niemcunowicz-Janica; Sławomir Dobrzycki; Włodzimierz J Musial; Karol A Kaminski
Journal:  Heart Vessels       Date:  2014-08-26       Impact factor: 2.037

Review 8.  Mass Spectrometry-Based Proteomic Study Makes High-Density Lipoprotein a Biomarker for Atherosclerotic Vascular Disease.

Authors:  Chiz-Tzung Chang; Chao-Yuh Yang; Fuu-Jen Tsai; Shih-Yi Lin; Chao-Jung Chen
Journal:  Biomed Res Int       Date:  2015-05-18       Impact factor: 3.411

Review 9.  Serum paraoxonase 1 (PON1) measurement: an update.

Authors:  Jose J Ceron; Fernando Tecles; Asta Tvarijonaviciute
Journal:  BMC Vet Res       Date:  2014-03-25       Impact factor: 2.741

10.  Paraoxonase 1 activities and polymorphisms in autism spectrum disorders.

Authors:  Sergiu P Paşca; Eleonora Dronca; Bogdan Nemeş; Tamás Kaucsár; Emõke Endreffy; Felicia Iftene; Ileana Benga; Rodica Cornean; Maria Dronca
Journal:  J Cell Mol Med       Date:  2009-06-28       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.